Risk factors of lymphoma for patients receiving anti-TNF agents (multivariate analysis: main analysis and analysis restricted to RA patients)
| OR (95% CI) | p Value | |
| All lymphoma (37 cases and 74 controls) | ||
| Last anti-TNF agent received | ||
| Etanercept | 1 | |
| Adalimumab | 4.73 (1.27 to 17.65) | 0.02 |
| Infliximab | 4.12 (1.36 to 12.49) | 0.01 |
| Time from onset of first anti-TNF treatment* | ||
| <2 years | 3.30 (1.17 to 9.30) | 0.02 |
| ⩾2 years | 1 (Ref) | |
| Lymphoma in RA patients (27 cases and 54 controls) | ||
| Last anti-TNF agent received | ||
| Etanercept | 1 | 0.003 |
| Adalimumab or infliximab | 6.68 (1.90 to 23.54) | |
*Time from onset of the last anti-TNF treatment and first symptoms of lymphoma for cases, time from onset of the last anti-TNF treatment and last news for controls. OR, odds ratio; RA, rheumatoid arthritis.